Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
S
MAY 5, 2009VOLUME 53, NO. 18
JOURNAL of the AMERICAN COLLEGE of CARDIOLOGY
Inside This Issue
STATE-OF-THE-ART PAPERA
Ttbdpgt
L
PGR
DsMia1pDucs
TATE-OF-THE-ART PAPER
1621Nephrogenic Systemic Fibrosis
ndreas Kribben, Oliver Witzke, Uwe Hillen, Jörg Barkhausen, Anton E. Daul, Raimund Erbel
his overview summarizes the current knowledge about the pathogenesis, diagnosis, andherapy for nephrogenic systemic fibrosis (NSF). NSF is characterized by skin induration thategins in the extremities. Involvement of internal organs occurs, which ultimately leads toeath. Exposure to gadolinium-based magnetic resonance (MR) contrast media, especially inatients with renal dysfunction, seems to be the inciting event. To reduce the risk of NSF,adolinium-based MR contrast media should be avoided in patients with renal failure unless
he diagnostic information is essential and not available with other imaging techniques.LATE-BREAKING CLINICAL TRIAL
ATE-BREAKING CLINICAL TRIAL1629Improved Mortality Seen With DES in Registry of Medicare Patients
amela S. Douglas, J. Matthew Brennan, Kevin J. Anstrom, Art Sedrakyan, Eric L. Eisenstein,hazala Haque, David Dai, David F. Kong, Bradley Hammill, Lesley Curtis, David Matchar,alph Brindis, Eric D. Peterson
ouglas and colleagues combined datasets from the National Cardiovascular Data Registryites for coronary percutaneous coronary intervention (PCI) during 2004 to 2006 with
edicare inpatient claims data for follow-up outcomes. Drug-eluting stents (DES) weremplanted in 217,675 patients and bare-metal stents (BMS) in 45,025 patients. At 30 monthsnd after propensity score adjustment, DES patients had lower rates of death (13.5% vs.6.5%, hazard ratio [HR]: 0.75) and myocardial infarction (7.5 of 100 patients vs. 8.9 of 100atients, HR: 0.77), with minimal differences in revascularization, stroke, and bleeding. TheES survival benefit was observed in all subgroups analyzed and persisted throughout follow-
p. In this largest ever real-world study, patients receiving DES had significantly betterlinical outcomes than their BMS counterparts, without an associated increase in bleeding or
troke.(continued on page A-20)
C
MAY 5, 2009 (continued) A-20
CLINICAL RESEARCH
Mark A. Hlatky, p. 1651
UQMS
HpinScmsIld
I
JE
Kieiptvt
I
O
Fevwstwds
LINICAL TRIALS
1642Coronary CTA for Early Triage of Patients With Acute Chest Pain
Editorial Comment
do Hoffmann, Fabian Bamberg, Claudia U. Chae, John H. Nichols, Ian S. Rogers, Sujith K. Seneviratne,uynh A. Truong, Ricardo C. Cury, Suhny Abbara, Michael D. Shapiro, Jamaluddin Moloo, Javed Butler,aros Ferencik, Hang Lee, Ik-Kyung Jang, Blair A. Parry, David F. Brown, James E. Udelson,
tephan Achenbach, Thomas J. Brady, John T. Nagurney
offmann and colleagues performed coronary computed tomography angiography (CTA) inatients who presented to the emergency room with acute chest pain and were at low orntermediate risk for acute coronary syndromes (ACS). The results of the coronary CTA wereot shared with the treating physicians. Of almost 400 subjects enrolled, 8% had ACS.ensitivity and negative predictive value for ACS were both 100% for subjects with nooronary artery disease (CAD) on coronary CTA; there were no complications during the 6onths of follow-up in these subjects. Both the extent of coronary plaque and the presence of
tenosis predicted ACS independently and incrementally to Thrombolysis In Myocardialnfarction risk score. In this study, patients with acute chest pain and low to intermediateikelihood of ACS who are free of CAD by coronary CTA may be candidates for early
ischarge.NTERVENTIONAL CARDIOLOGY
1653Less Coronary Endothelial Dysfunction With ZES Compared With SES
in Won Kim, Hong Seog Seo, Jae Hyoung Park, Jin Oh Na, Cheol Ung Choi, Hong-Eui Lim,ung Ju Kim, Seung-Woon Rha, Chang Gyu Park, Dong Joo Oh
im and colleagues studied coronary endothelial dysfunction 6 months after stentmplantation in patients randomzied to either a zotarolimus-eluting stent (ZES), a sirolimus-luting stent (SES), or a bare-metal stent (BMS). Endothelial function was assessed withncremental acetylcholine (Ach) and nitrate infusions and quantitatively measured bothroximal and distal to the stent. More intense vasoconstriction to Ach was seen with SEShan with ZES; both were more pronounced than BMS. Endothelium-independentasodilation to nitrate did not differ. ZES seems to provoke less endothelial dysfunction in
he distal coronary artery compared with SES.NTERVENTIONAL CARDIOLOGY
1660Examining the Effects of Diabetes on Rates of Restenosis
le Fröbert, Bo Lagerqvist, Jörg Carlsson, Johan Lindbäck, Ulf Stenestrand, Stefan K. James
röbert and colleagues used the SCAAR (Swedish Angiography and Angioplasty Registry) tovaluate the impact of diabetes mellitus (DM) on restenosis rates in patients treated with aariety of different drug-eluting stents (DES) in a real-world setting. The rate of restenosisas 1.2 times higher in patients with DM compared to patients without DM. There were
ignificant differences among the stents; the rate of restenosis in subjects with DM was 2imes higher with the zotarolimus-eluting compared to the other stents. In this large real-orld registry, DM significantly increased the risk of restenosis; further studies are needed toetermine if zotarolimus increases the risk of restenosis in DM or if this finding reflected
election bias in this nonrandomized study.(continued on page A-23)
I
MAY 5, 2009 (continued) A-23
Sorin J. Brener, p. 1674
G
WowiLpsITba
I
SG
Ts(ms(W(wwe
A
RA
AkaSorsig
NTERVENTIONAL CARDIOLOGY
1668Meta-Analysis Suggests Equivalency of GP IIb/IIIa Inhibitors for Primary PCI
DEATHxif( ROthgieW)dexif( ROseluceloMllamSbamixicbAydutS ed)IC %59%IC %59N/nN/n
Favors Abciximab Favors Small Molecules
DANZI 0/50 0/50 Not estimableERNST 0/30 1/29 7.01 0.31 [0.01, 7.96] EVA-AMI 7/201 8/226 33.95 0.98 [0.35, 2.76] FATA 5/341 7/351 31.75 0.73 [0.23, 2.33] MULTISTRATEGY 9/372 4/372 18.23 2.28 [0.70, 7.47] STRATEGY 3/88 2/87 9.07 1.50 [0.24, 9.20]
Total (95% CI) 24/1082 22/1115 100.00 1.14 [0.64, 2.04]
Test for heterogeneity: Chi² = 2.66, df = 4 (P = 0.62) , I² = 0%Test for overall effect: Z = 0.44 (P = 0.66)
0.1 0.2 0.5 1 2 5 10
Editorial Comment
iuseppe De Luca, Grazia Ucci, Ettore Cassetti, Paolo Marino
hile the addition of glycoprotein (GP) IIb/IIIa inhibitors have shown improvedutcomes in ST-segment elevation myocardial infarction (STEMI) patients treatedith primary percutaneous coronary intervention (PCI) in most studies, it is unclear
f abciximab is superior to the small molecule agents tirofiban and eptifibatide. Deuca and colleagues performed a meta-analysis of 6 trials that randomized over 2,000rimary PCI patients to either abciximab or a small molecule agent. There were noignificant differences in rates of post-procedural Thrombolysis In Myocardialnfarction flow grade 3, ST-segment resolution, reinfarction, or 30-day mortality.his meta-analysis shows that among STEMI patients undergoing primary PCI,oth abciximab and small molecule GP IIb/IIIa inhibitors have similar efficacy for
ngiographic, electrocardiographic, and clinical outcomes.NTERVENTIONAL CARDIOLOGY
1677Meta-Analysis Shows Improved Outcomes for STEMI Patients Treated With DES
omjot S. Brar, Martin B. Leon, Gregg W. Stone, Roxana Mehran, Jeffrey W. Moses, Simerjeet K. Brar,eorge Dangas
he primary aim of the analysis by Brar and colleagues was to compare outcomes bytent type for death, myocardial infarction (MI), target vessel revascularizationTVR), and stent thrombosis in randomized trials of ST-segment elevationyocardial infarction (STEMI) patients. Thirteen randomized trials with over 7,000
ubjects were identified. Compared with bare-metal stents (BMS), drug-eluting stentsDES) significantly reduced TVR without increasing death, MI, or stent thrombosis.
hen reports were included from 18 registries that enrolled STEMI patientsn � 26,521), DES significantly reduced TVR without an increase in MIs. Deathas significantly lower in the DES group within 1 year of the index PCI, but thereere no differences within 2 years. In conclusion, the use of DES appears safe and
fficacious in randomized trials and registries of patients with STEMI.
RRHYTHMIAS AND HEART FAILURE
1690Low Rates of Use of Evidence-Based Therapies in Patients With AF and HF
obby Nieuwlaat, Luc W. Eurlings, John G. Cleland, Stuart M. Cobbe, Panos E. Vardas,lessandro Capucci, José L. Lopez-Sendòn, Joan G. Meeder, Yigal M. Pinto, Harry J. G. M. Crijns
trial fibrillation (AF) and heart failure (HF) often coexist in patients and arenown to worsen each other’s prognosis. Little is known about how this combinationffects the use of evidence-based therapies in clinical practice. The Euro Hearturvey on AF, followed over 5,000 patients with AF from 35 countries. At baseline,ne-third of these subjects had HF. The presence of AF was associated with aeduction in the use of guideline-recommended therapy for HF with left ventricularystolic dysfunction (LVSD), such as beta-blockers or angiotensin-converting enzymenhibitors. The combination of AF and LVSD appears to reduce the use of
uideline-recommended drug therapy for both conditions.(continued on page A-24)
C
MAY 5, 2009 (continued) A-24
KKJ
TterMDmp
C
Gerard Pasterkamp, p. 1716
CJ
Cncrta(ca
F
M
DKM
Pdaoanarpr
ARDIAC IMAGING
1699MDCT May Be More Useful for Studying Peri-Infarct Tissue Than Cardiac MRI
arl H. Schuleri, Marco Centola, Richard T. George, Luciano C. Amado, Kristine S. Evers,akuya Kitagawa, Andrea L. Vavere, Robert Evers, Joshua M. Hare, Christopher Cox, Elliot R. McVeigh,
oão A. C. Lima, Albert C. Lardo
he use of cardiac multidetector computed tomography (MDCT) has been expanded beyondhe assessment of coronary atherosclerosis to include myocardial viability by delayed-contrastnhancement (DE). Schuleri and colleagues compared MDCT and cardiac magneticesonance imaging (MRI) to evaluate the peri-infarct zone (PIZ) in a porcine model. DE-
DCT demonstrated excellent correlation of infarct size with post-mortem pathology andE-MRI. DE-MDCT and -MRI both detected a PIZ in all animals, which correlated to aixture of viable and nonviable myocytes by histology. Further studies showed that DE-MDCT
rovided a more detailed assessment that was less susceptible to partial volume effects than MRI.
ARDIAC IMAGING
1708Positive Coronary Artery Remodeling Detected by MRI
Editorial Comment
uilian Miao, Shaoguang Chen, Robson Macedo, Shenghan Lai, Kiang Liu, Debiao Li, Bruce A. Wasserman,ens Vogel-Clausen, João A. C. Lima, David A. Bluemke
oronary artery disease (CAD) is currently defined as clinically significant when luminalarrowing is present. However, in early atherosclerosis, the first arterial changes consist ofompensatory enlargement of both the outer wall of the vessel and the lumen (positiveemodeling). Miao and colleagues reviewed data from magnetic resonance imaging (MRI) inhe MESA trial to determine if positive remodeling could be identified with MRI insymptomatic subjects. Positive remodeling was confirmed with increases in both vessel sizeouter diameter) and lumen area that correlated with increases in wall thickness. This studyonfirms that coronary wall MRI can detect arterial remodeling in subjects with subclinical
therosclerosis.FROM AROUND THE WORLD
OCUS ON INDIA1718ultimodality Intervention Significantly
Improves Cardiac Risk Factors in Indian Population34.1
25.426.8
34.7
0
5
10
15
20
25
30
35
40
Intervention Control
Per
cen
tag
e %
Baseline Final
orairaj Prabhakaran, Panniyammakal Jeemon, Shifalika Goenka, Ramakrishnan Lakshmy,. R. Thankappan, Faruq Ahmed, Prashant P. Joshi, B. V. Murali Mohan, Ramanathan Meera,ohas S. Das, Ramesh C. Ahuja, Ram Kirti Saran, Vivek Chaturvedi, K. Srinath Reddyrabhakaran and colleagues hypothesized that a comprehensive program for cardiovascularisease (CVD) risk factor reduction could be successful on a large scale. The intervention wasmultipronged strategy of health promotion, high-risk primary prevention, and policy-levelr environmental changes, such as banning smoking in buildings and changing menu itemsvailable at cafeterias. Favorable changes were observed in all of the CVD risk factors overearly 4 years of follow-up; these changes included an almost 10% reduction in blood sugarnd a 3% reduction in systolic blood pressure, compared to increases of 13% and 8%,espectively, in the control population. This comprehensive worksite-based interventionrogram was effective in reducing CVD risk factors, and would likely be cost-effective by
educing cardiovascular events.